CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 22, 2009--
Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE),
today announced the global commercial availability of a new capillary
electrophoresis (CE) sequencing system. The 3500 Series Genetic Analyzer
builds on Applied Biosystems’ industry-leading CE sequencing systems,
with state-of-the-art advancements, setting significant new standards
for throughput, data quality and ease of use. The 3500 Series Genetic
Analyzer is for research use only not intended for therapeutic or
diagnostic use.
Since May 2009, more than 10 research institutions have been
participating in an early evaluation of the technology with primary
interest in studying the most widely recognized human genetic disorders,
such as those caused by extra or missing chromosomes, as well as a broad
spectrum of other diseases. Some of the global research institutions
participating in the early evaluation program are the Peter MacCallum
Cancer Centre, Australia; Massachusetts General Hospital, USA; Institute
Paoli Calmette, France; University College London Hospital, United
Kingdom; Silvestrini Hospital Molecular, Italy; Laboratório de Genômica
e Biologia Molecular, Centro de Pesquisa – Hospital A. C. Camargo,
Brazil; Transcriptome Research Group, National Institute of Radiological
Sciences, Japan; and University of Tokyo, Japan.
The 3500 Series enables researchers to run up to 1,100 sequencing or
1,200 genotyping samples per day. It features novel consumable designs
that incorporate the ability to track key information with radio
frequency identification (RFID) tags, new optical and thermal systems
designs, and redesigned data collection and analysis software, which
enables easy generation of cost-effective analyses and high-quality data.
Many institutions perform studies in areas such as viral/microbial
typing, tissue pathology studies, cancer and other disease research,
employing DNA sequencing and fragment analysis applications using CE
technology. One such example, the Diagnostic Molecular Pathology
Laboratory at Massachusetts General Hospital, is currently using the
3500 system in its research studies. Dr.
John Iafrate leads the clinical service laboratory at the hospital,
which conducts specialized molecular DNA oncology research. Dr. Iafrate
recently purchased a 3500 Genetic Analyzer.
Dr. Iafrate and his team are using Applied Biosystems CE technology in a
variety of pre-clinical studies to investigate potential correlations
between genetic mutations and the formation of disease, including
cancer. The range of research tests using CE technology include
microsatellite instability analyses, sequencing, and higher-throughput
genotyping of various cancer tissues to aid cancer research.
Kip Miller, President, Genetic Systems Division at Life Technologies
“The commercialization of the Applied Biosystems 3500 Genetic Analyzer
demonstrates our commitment to innovation in DNA sequencing. We expect
that highly automated and simplified solutions enabling cost-effective
analyses, and repeatable high-quality data will allow researchers to
broaden their applications for this technology, and will meet our
customers’ growing demand for advanced genomic analysis systems.”
Resources
About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology
tools company dedicated to improving the human condition. Our systems,
consumables and services enable researchers to accelerate scientific
exploration, driving to discoveries and developments that make life even
better. Life Technologies customers do their work across the biological
spectrum, working to advance personalized medicine, regenerative
science, molecular diagnostics, agricultural and environmental research,
and 21st century forensics. Life Technologies had sales of more than $3
billion in 2008, employs approximately 9,500 people, has a presence in
more than 100 countries, and possesses a rapidly growing intellectual
property estate of approximately 3,600 patents and exclusive licenses.
Life Technologies was created by the combination of Invitrogen
Corporation and Applied Biosystems Inc. For more information on how we
are making a difference please visit our website: www.lifetechnologies.com.
Follow Life Technologies on Twitter @LIFECorporation
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies’ plans,
objectives, expectations and strategy for its business, contains
forward-looking statements that are subject to risks and uncertainties
that could cause actual results or events to differ materially from
those expressed or implied by such forward-looking statements. Any
statements that are not statements of historical fact are
forward-looking statements. When used, the words “believe,” “plan,”
“intend,” “anticipate,” “target,” “estimate,” “expect” and the like,
and/or future tense or conditional constructions (“will,” “may,”
“could,” “should,” etc.), or similar expressions, identify certain of
these forward-looking statements. Important factors which could cause
actual results to differ materially from those in the forward-looking
statements are detailed in filings made by Life Technologies with the
Securities and Exchange Commission. Life Technologies undertakes no
obligation to update or revise any such forward-looking statements to
reflect subsequent events or circumstances.
The 3500 Series systems are for research use only. Not
intended for any animal or human therapeutic or diagnostic use.
Copyright 2009. Life Technologies Corporation. All rights reserved. AB
(Design), and Applied Biosystems are registered trademarks of Life
Technologies or its subsidiaries in the United States and/or certain
other countries.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6080064&lang=en
Source: Life Technologies Corporation
Life Technologies
Lauren Lum, 650-638-6916
lauren.lum@lifetech.com
